Plastic Meets Biology is creating first‑in‑class enzyme therapeutics that target and break down microplastics within the human body. By removing these particles, the treatments aim to mitigate cardiometabolic disease risk associated with microplastic exposure.
Funding
Funding not disclosed
Founders
Product
Problem
Microplastic particles accumulate in human tissues and have been linked to chronic inflammation and increased risk of cardiometabolic diseases. Current medical approaches do not address the removal of these persistent plastic particles from the body.
Solution
Plastic Meets Biology develops engineered enzyme therapeutics designed to degrade and eliminate microplastics within the human body. By targeting the polymer structures of common microplastics, these enzymes break them down into harmless metabolites that can be safely cleared. The platform leverages protein engineering and biocatalysis to create first‑in‑class biologics with high specificity for plastic polymers. Reducing microplastic burden aims to lower systemic inflammation and improve metabolic health outcomes for patients at risk of cardiometabolic disease.
Target Audience
Primary customers are pharmaceutical developers and healthcare providers seeking therapeutic options for patients with cardiometabolic risk linked to microplastic exposure.
Features
- Engineered enzymes optimized for catalytic degradation of prevalent microplastic polymers
- Biologic formulation suitable for systemic administration and tissue distribution
- High substrate specificity to minimize off‑target activity on endogenous biomolecules
- Scalable protein production using recombinant expression systems
- Preclinical data demonstrating reduction of plastic particle load and inflammatory markers